Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
NCT ID: NCT02648711
Last Updated: 2020-05-28
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
PHASE1
Total Enrollment
41 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-10-31
Study Completion Date
2018-05-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of weekly dosing of CRLX101 (both as monotherapy; (Schedule 1) and in combination with bevacizumab every 2 weeks (Schedule 2) and weekly with a 3 week on / 1 week off schedule in combination with mFOLFOX6 (Schedule 3) to affirm the dose for future clinical studies.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
NCT02380677
Advanced Solid Tumor Malignancy
TERMINATED
PHASE1/PHASE2
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06630247
Solid Cancers
Solid Tumor Cancer
Solid Tumor Malignancy
+4 more
TERMINATED
PHASE1
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674
Ovarian Cancer, Epithelial
Gastric Cancer
GastroEsophageal Junction (GEJ) Cancer
+11 more
RECRUITING
PHASE1
Study of Intravenous RXDX-107 in Patients With Solid Tumors
NCT02548390
Solid Tumor
TERMINATED
PHASE1
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
NCT02711137
Solid Tumors
TERMINATED
PHASE1/PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is an open-label, dose escalation study. Subjects enrolled in Schedule 1 will receive weekly CRLX101 alone. The starting dose for Schedule 1 is 12 mg/m\^2 and the next dose level is 15 mg/m\^2 (or 10 mg/m\^2 if 12 mg/m\^2 is not well tolerated). No other dose levels in Schedule 1 will be explored.
Subjects enrolled in Schedule 2 will receive weekly CRLX101 in combination with bi-weekly bevacizumab (10 mg/kg) The starting dose for Schedule 2 is 12 mg/m\^ and the next dose is 15 mg/m\^2. No other dose levels in Schedule 2 will be explored
Subjects enrolled in Schedule 3 will receive weekly CRLX101 for 3 of every 4 weeks in combination with bi-weekly mFOLFOX6 (oxaliplatin 85 mg/m\^2, leucovorin 400 mg/m\^2 and 5FU (fluorouracil) 400 mg/m\^2 bolus followed by 2400 mg/m\^2 continuous infusion). The starting dose for Schedule 3 is 12 mg/m\^2 and the next dose is 15 mg/m\^2.
In the absence of dose-limiting toxicities (DLTs) additional subjects may be enrolled (expansion cohort) at the same, intermediate or lower dose levels following consultation between the Investigator and Sponsor.
Enrollment of 6-8 subjects will occur in each cohort for all 3 Schedules.
The MTD is defined as the highest dose level at which fewer than 2 out of 6 subjects experience a DLT. RP2D will be selected based on overall tolerability data from all subjects treated at different dose cohorts in this study.
No intra-patient dose escalation is allowed.
Approximately 61 evaluable subjects are anticipated to be enrolled: 15 subjects in Schedule 1, 15 subjects in Schedule 2 and approximately 31 subjects are anticipated in Schedule 3 (approximately 16 in the dose escalation cohort and up to 15 in the expansion cohort).
The exact number of subjects is dependent on the actual number of subjects enrolled per cohort and the number of cohorts investigated.
Subjects enrolled in Schedule 2 will receive weekly CRLX101 in combination with bi-weekly bevacizumab (10 mg/kg) The starting dose for Schedule 2 is 12 mg/m\^ and the next dose is 15 mg/m\^2. No other dose levels in Schedule 2 will be explored
Subjects enrolled in Schedule 3 will receive weekly CRLX101 for 3 of every 4 weeks in combination with bi-weekly mFOLFOX6 (oxaliplatin 85 mg/m\^2, leucovorin 400 mg/m\^2 and 5FU (fluorouracil) 400 mg/m\^2 bolus followed by 2400 mg/m\^2 continuous infusion). The starting dose for Schedule 3 is 12 mg/m\^2 and the next dose is 15 mg/m\^2.
In the absence of dose-limiting toxicities (DLTs) additional subjects may be enrolled (expansion cohort) at the same, intermediate or lower dose levels following consultation between the Investigator and Sponsor.
Enrollment of 6-8 subjects will occur in each cohort for all 3 Schedules.
The MTD is defined as the highest dose level at which fewer than 2 out of 6 subjects experience a DLT. RP2D will be selected based on overall tolerability data from all subjects treated at different dose cohorts in this study.
No intra-patient dose escalation is allowed.
Approximately 61 evaluable subjects are anticipated to be enrolled: 15 subjects in Schedule 1, 15 subjects in Schedule 2 and approximately 31 subjects are anticipated in Schedule 3 (approximately 16 in the dose escalation cohort and up to 15 in the expansion cohort).
The exact number of subjects is dependent on the actual number of subjects enrolled per cohort and the number of cohorts investigated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Solid Tumors
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CRLX101 alone
Subjects will receive weekly infusion of CRLX101 alone. Starting dose is 12 mg/m\^2 and the next dose level is 15 mg/m\^2 (or 10 mg/m\^2 if 12 mg/m\^2 is not well tolerated. No other dose levels will be explored.
Group Type
EXPERIMENTAL
CRLX101
Intervention Type
DRUG
infusion CRLX101 weekly
CRLX101 in combination with bevacizumab
Subjects receive weekly infusion of CRLX101 in combination with bi-weekly bevacizumab (10 mg/kg. The starting dose is 12 mg/m\^2 and the next dose level is 15 mg/m\^2. No other dose levels will be explored.
Group Type
EXPERIMENTAL
CRLX101
Intervention Type
DRUG
infusion CRLX101 weekly
Bevacizumab
Intervention Type
DRUG
infusion weekly CRLX101 + bevacizumab biweekly
CRLX101 in combination with mFOLFOX6
Subjects receive weekly infusion of CRLX101 for 3 of every 4 weeks in combination with bi-weekly mFOLFOX6 (oxaliplatin 85 mg/m\^2, leucovorin 400 mg/m\^2 and 5FU 400 mg/m\^2 bolus followed by 2400 mg/m\^2 continuous infusion). The starting dose is 12 mg/m\^2 and the next dose level is 15 mg/m\^2.
Group Type
EXPERIMENTAL
CRLX101
Intervention Type
DRUG
infusion CRLX101 weekly
mFOLFOX6
Intervention Type
DRUG
infusion weekly CRLX101 for 3 or every 4 weeks and in combination with bi-weekly mFOLFOX6
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CRLX101
infusion CRLX101 weekly
Intervention Type
DRUG
Bevacizumab
infusion weekly CRLX101 + bevacizumab biweekly
Intervention Type
DRUG
mFOLFOX6
infusion weekly CRLX101 for 3 or every 4 weeks and in combination with bi-weekly mFOLFOX6
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
NLG207
Avastin
oxaliplatin, leucovorin, 5FU
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female adult subjects ≥18 years of age
* Diagnosis of histologically or cytologically confirmed for:
* For Schedule 1 and 2: advanced solid tumor malignancy that is refractory to standard therapy and/or for whom no further standard therapy is available
* For Schedule 3: advanced/metastatic tumors for which mFOLFOX6 is appropriate, or advanced/metastatic tumors that may be sensitive to each component of mFOLFOX6 or sensitive to topoisomerase 1 inhibitors including pancreatic, colorectal, esophageal, gastric, bladder or ovarian cancer, triple-negative breast cancer, small cell lung cancer (SCLC), cholangiocarcinoma, among others
* For Schedules 1 and 2: Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2, For Schedule 3: ECOG Performance Status of 0 or 1
* Life expectancy \>12 weeks in the opinion of the Investigator
* Subjects with acceptable pre-study\* hematology and biochemistry labs ≤3 days prior to Week 1 Day 1 (W1D1) defined as:
* absolute neutrophil count (ANC) ≥1.500 cells / µL (1.5 x 10°/L, without growth factor support
* platelet count ≥100,000 cells/µL (100 x 10° cells/L), without growth factor support
* hemoglobin ≥9 g/dL (90/g/L)
* serum total bilirubin ≤1.5 upper limit of normal (ULN), unless Gilbert's disease
* alanine transaminase (ALT) or aspartate transaminase (AST) ≤2.5 x ULN, (5 x ULN for subjects with liver metastases)
* calculated or measured creatinine clearance ≥40 mL/min
* NOTE: If screening hematology and biochemistry labs are performed ≤3 days prior to W1D1, additional pre-study labs do not need to be repeated to confirm eligibility. However, if screening hematology and biochemistry labs are performed greater than 3 days prior to W1D1, additional pre-study labs will need to be performed to confirm continued eligibility to ensure labs remain acceptable per protocol
* Females of childbearing potential must agree to use two effective methods of contraception (or abstain completely from heterosexual intercourse) from the time of informed consent and for 30 days following last dose of study drug
* NOTE: Females of childbearing potential are defined as women physically capable of becoming pregnant unless the female subject cannot have children due to surgery or other medical reasons (effective tubal ligation, ovaries or the uterus removed, or are post-menopausal). Fertile males of childbearing potential are defined as men who are sexually capable to impregnate the female partner even if surgically sterilized (i.e., vasectomy).
* highly effective methods of contraception include intra-uterine device (IUD) and hormonal contraception (oral, injectable, patches or implant)
* effective methods of contraception include barrier methods (latex condom, diaphragm with spermicide, cervical cap, sponge)
* when possible, subjects should be strongly encouraged to include at least one highly effective method of contraception
* Male subjects must agree to use appropriate method of barrier contraception (latex condom with a spermicidal agent) or abstain completely from heterosexual intercourse fro the time of informed consent and for 120 days following last dose of study drug unless female partner absolutely cannot have children because of surgery or for other medical reasons
* Negative urine pregnancy test
* Ability to understand and willingness to sign a written informed consent form
* Able to comply with study visit schedule and assessments
* Diagnosis of histologically or cytologically confirmed for:
* For Schedule 1 and 2: advanced solid tumor malignancy that is refractory to standard therapy and/or for whom no further standard therapy is available
* For Schedule 3: advanced/metastatic tumors for which mFOLFOX6 is appropriate, or advanced/metastatic tumors that may be sensitive to each component of mFOLFOX6 or sensitive to topoisomerase 1 inhibitors including pancreatic, colorectal, esophageal, gastric, bladder or ovarian cancer, triple-negative breast cancer, small cell lung cancer (SCLC), cholangiocarcinoma, among others
* For Schedules 1 and 2: Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2, For Schedule 3: ECOG Performance Status of 0 or 1
* Life expectancy \>12 weeks in the opinion of the Investigator
* Subjects with acceptable pre-study\* hematology and biochemistry labs ≤3 days prior to Week 1 Day 1 (W1D1) defined as:
* absolute neutrophil count (ANC) ≥1.500 cells / µL (1.5 x 10°/L, without growth factor support
* platelet count ≥100,000 cells/µL (100 x 10° cells/L), without growth factor support
* hemoglobin ≥9 g/dL (90/g/L)
* serum total bilirubin ≤1.5 upper limit of normal (ULN), unless Gilbert's disease
* alanine transaminase (ALT) or aspartate transaminase (AST) ≤2.5 x ULN, (5 x ULN for subjects with liver metastases)
* calculated or measured creatinine clearance ≥40 mL/min
* NOTE: If screening hematology and biochemistry labs are performed ≤3 days prior to W1D1, additional pre-study labs do not need to be repeated to confirm eligibility. However, if screening hematology and biochemistry labs are performed greater than 3 days prior to W1D1, additional pre-study labs will need to be performed to confirm continued eligibility to ensure labs remain acceptable per protocol
* Females of childbearing potential must agree to use two effective methods of contraception (or abstain completely from heterosexual intercourse) from the time of informed consent and for 30 days following last dose of study drug
* NOTE: Females of childbearing potential are defined as women physically capable of becoming pregnant unless the female subject cannot have children due to surgery or other medical reasons (effective tubal ligation, ovaries or the uterus removed, or are post-menopausal). Fertile males of childbearing potential are defined as men who are sexually capable to impregnate the female partner even if surgically sterilized (i.e., vasectomy).
* highly effective methods of contraception include intra-uterine device (IUD) and hormonal contraception (oral, injectable, patches or implant)
* effective methods of contraception include barrier methods (latex condom, diaphragm with spermicide, cervical cap, sponge)
* when possible, subjects should be strongly encouraged to include at least one highly effective method of contraception
* Male subjects must agree to use appropriate method of barrier contraception (latex condom with a spermicidal agent) or abstain completely from heterosexual intercourse fro the time of informed consent and for 120 days following last dose of study drug unless female partner absolutely cannot have children because of surgery or for other medical reasons
* Negative urine pregnancy test
* Ability to understand and willingness to sign a written informed consent form
* Able to comply with study visit schedule and assessments
Exclusion Criteria
* Subject has received:
* chemotherapy or small molecular targeted therapy \<2 weeks prior to W1D1
* approved antibody therapy \<5 half-lives from W1D1 (or 4 weeks since last therapy, whichever is the shortest)
* local palliative radiation \<14 days from W1D1
* invasive surgery requiring general anesthesia \<30 days from W1D1
* chemotherapy with nitrosoureas or mitomycin C \<45 days from W1D1
* Uncontrolled grade 2 or greater toxicity except alopecia related to any prior treatment (i.e., chemotherapy, targeted therapy, radiation or surgery) within 7 days prior to W1D1 unless approved by the Medical Monitor
* Prolongation of QT/QTc interval (QTc interval \>470) using the Fredericia method of QTc analysis
* Women who are pregnant or nursing
* Any known human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS) or any concurrent infection requiring IV antibiotics
* Any known clinically significant or concurrent acute liver disease, including viral hepatitis
* Primary brain malignant tumors
* Subjects with uncontrolled symptomatic central nervous system (CNS) involvement
* Subjects requiring steroids at stable dose (\>4 mg/day dexamethasone or equivalent) for at least 2 weeks
* Uncontrolled hypertension \>150/100 mmHg
* Concurrent participation in any other investigational therapeutic study, unless non-interventional study and approved by Sponsor
* History of stroke, deep venous thrombosis (DVT), transient ischemic attack (TIA), unstable angina, or myocardial infarction within 3 months prior to W1D1
* Uncontrolled concurrent disease or illness including but not limited to:
* symptomatic congestive heart failure (NYHA Class III or IV) per the NYHA Classification, unstable angina pectoris, clinically significant cardiac arrhythmia
* unstable or untreated cardiac conditions or ejection fraction of \<50% as determined by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)
* diabetes mellitus (i.e., fasting blood glucose \>220 despite acceptable chronic diabetes therapy)
* psychiatric illness that would limit compliance with study requirements, as determined by the Investigator
* Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or that may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for the study.
* Known hypersensitivity to any component of CRLX101 or excipient or documented medical condition that would prohibit adequate pre-medication with antihistamine.
* Presence of ≥Grade 1 cystitis
* Minor surgical procedure, excluding placement of a vascular access device, within 24 hours prior to W1D1.
* Cardiovascular disease defined as congestive heart failure (NYHA Class II, III, or IV) per the NYHA Classification, angina pectoris requiring nitrate therapy, or myocardial infarction within the last 6 months prior to therapy
* Uncontrolled hypertension (defined as the presence of systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg on two separate occasions. Blood pressure must be controlled to a systolic blood pressure \<150 mmHg and/or to diastolic blood pressure \<100 mmHg prior to study treatment), or any prior history of hypertensive crisis or hypertensive encephalopathy
* Peripheral vascular disease \>Grade 1
* Known congenital long QT syndrome, history of torsades de pointes or ventricular tachycardia.
* Known history of pulmonary hypertension or non-infectious interstitial pneumonitis.
* History or evidence of thrombotic or hemorrhagic disorders: including cerebrovascular accident (CVA) / stroke or transient ischemic attack (TIA), intracerebral hemorrhage or sub- arachnoid hemorrhage ≤ 6 months prior to W1D1
* Chronic daily aspirin \>325 mg/day or clopidogrel (\>75 mg/day)
* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to randomization
* Any of the following serious, non-healing conditions:wound, ulcer, or bone fracture
* Proteinuria at screening as demonstrated by either: urine dipstick ≥2+ (subjects discovered to have a ≥2+ proteinuria on dipstick urinalysis at baseline should undergo 24-hour urine collection and must demonstrate \<1g of protein in 24 hours to be eligible): 24-hour urine collection demonstrates \>1g of protein in 24 hours
* Immunocompromised subjects, including known seropositivity for human immunodeficiency virus (HIV), or current or chronic hepatitis B and/or hepatitis C infection (as detected by positive testing for hepatitis B surface antigen \[HbsAg\] or antibody to hepatitis C virus \[anti HCV\] with confirmatory testing). \[Note: testing is not mandatory to be eligible for the study. However, if a subject is at risk for having undiagnosed hepatitis C virus (HCV) (due to history of injection drug use or due to geographic location for example), testing at screening should be considered\]
* Chronic treatment with corticosteroids (prednisone \>12.5 mg/day or dexamethasone \>2 mg/day excluding inhaled steroids
* Known hypersensitivity to 5FU, oxaliplatin or other platinum agent, or to their excipients
* Known dihydropyridine dehydrogenase (DPD) enzyme deficiency (testing not required)
* Baseline peripheral neuropathy grade ≥ 2
* Progressive disease within ≤ 6 months of completing an oxaliplatin containing adjuvant therapy
* Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
* chemotherapy or small molecular targeted therapy \<2 weeks prior to W1D1
* approved antibody therapy \<5 half-lives from W1D1 (or 4 weeks since last therapy, whichever is the shortest)
* local palliative radiation \<14 days from W1D1
* invasive surgery requiring general anesthesia \<30 days from W1D1
* chemotherapy with nitrosoureas or mitomycin C \<45 days from W1D1
* Uncontrolled grade 2 or greater toxicity except alopecia related to any prior treatment (i.e., chemotherapy, targeted therapy, radiation or surgery) within 7 days prior to W1D1 unless approved by the Medical Monitor
* Prolongation of QT/QTc interval (QTc interval \>470) using the Fredericia method of QTc analysis
* Women who are pregnant or nursing
* Any known human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS) or any concurrent infection requiring IV antibiotics
* Any known clinically significant or concurrent acute liver disease, including viral hepatitis
* Primary brain malignant tumors
* Subjects with uncontrolled symptomatic central nervous system (CNS) involvement
* Subjects requiring steroids at stable dose (\>4 mg/day dexamethasone or equivalent) for at least 2 weeks
* Uncontrolled hypertension \>150/100 mmHg
* Concurrent participation in any other investigational therapeutic study, unless non-interventional study and approved by Sponsor
* History of stroke, deep venous thrombosis (DVT), transient ischemic attack (TIA), unstable angina, or myocardial infarction within 3 months prior to W1D1
* Uncontrolled concurrent disease or illness including but not limited to:
* symptomatic congestive heart failure (NYHA Class III or IV) per the NYHA Classification, unstable angina pectoris, clinically significant cardiac arrhythmia
* unstable or untreated cardiac conditions or ejection fraction of \<50% as determined by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)
* diabetes mellitus (i.e., fasting blood glucose \>220 despite acceptable chronic diabetes therapy)
* psychiatric illness that would limit compliance with study requirements, as determined by the Investigator
* Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or that may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for the study.
* Known hypersensitivity to any component of CRLX101 or excipient or documented medical condition that would prohibit adequate pre-medication with antihistamine.
* Presence of ≥Grade 1 cystitis
* Minor surgical procedure, excluding placement of a vascular access device, within 24 hours prior to W1D1.
* Cardiovascular disease defined as congestive heart failure (NYHA Class II, III, or IV) per the NYHA Classification, angina pectoris requiring nitrate therapy, or myocardial infarction within the last 6 months prior to therapy
* Uncontrolled hypertension (defined as the presence of systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg on two separate occasions. Blood pressure must be controlled to a systolic blood pressure \<150 mmHg and/or to diastolic blood pressure \<100 mmHg prior to study treatment), or any prior history of hypertensive crisis or hypertensive encephalopathy
* Peripheral vascular disease \>Grade 1
* Known congenital long QT syndrome, history of torsades de pointes or ventricular tachycardia.
* Known history of pulmonary hypertension or non-infectious interstitial pneumonitis.
* History or evidence of thrombotic or hemorrhagic disorders: including cerebrovascular accident (CVA) / stroke or transient ischemic attack (TIA), intracerebral hemorrhage or sub- arachnoid hemorrhage ≤ 6 months prior to W1D1
* Chronic daily aspirin \>325 mg/day or clopidogrel (\>75 mg/day)
* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to randomization
* Any of the following serious, non-healing conditions:wound, ulcer, or bone fracture
* Proteinuria at screening as demonstrated by either: urine dipstick ≥2+ (subjects discovered to have a ≥2+ proteinuria on dipstick urinalysis at baseline should undergo 24-hour urine collection and must demonstrate \<1g of protein in 24 hours to be eligible): 24-hour urine collection demonstrates \>1g of protein in 24 hours
* Immunocompromised subjects, including known seropositivity for human immunodeficiency virus (HIV), or current or chronic hepatitis B and/or hepatitis C infection (as detected by positive testing for hepatitis B surface antigen \[HbsAg\] or antibody to hepatitis C virus \[anti HCV\] with confirmatory testing). \[Note: testing is not mandatory to be eligible for the study. However, if a subject is at risk for having undiagnosed hepatitis C virus (HCV) (due to history of injection drug use or due to geographic location for example), testing at screening should be considered\]
* Chronic treatment with corticosteroids (prednisone \>12.5 mg/day or dexamethasone \>2 mg/day excluding inhaled steroids
* Known hypersensitivity to 5FU, oxaliplatin or other platinum agent, or to their excipients
* Known dihydropyridine dehydrogenase (DPD) enzyme deficiency (testing not required)
* Baseline peripheral neuropathy grade ≥ 2
* Progressive disease within ≤ 6 months of completing an oxaliplatin containing adjuvant therapy
* Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NewLink Genetics Corporation
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
NewLink Ge
Role: STUDY_CHAIR
NewLink Genetics Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
START Midwest/Cancer & Hematology Centers of Western Michigan, PC
Grand Rapids, Michigan, United States
Site Status
MD Anderson Cancer Center
Houston, Texas, United States
Site Status
South Texas Accelerated Research Therapeutics (START), LLC
San Antonio, Texas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, Figg WD, Chen X, Turkbey IB, Choyke P, Murgo AJ, Doroshow JH, Melillo G. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1alpha in advanced solid tumors. Clin Cancer Res. 2011 Aug 1;17(15):5123-31. doi: 10.1158/1078-0432.CCR-11-0682. Epub 2011 Jun 14.
Reference Type
BACKGROUND
Eliasof S, Lazarus D, Peters CG, Case RI, Cole RO, Hwang J, Schluep T, Chao J, Lin J, Yen Y, Han H, Wiley DT, Zuckerman JE, Davis ME. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):15127-32. doi: 10.1073/pnas.1309566110. Epub 2013 Aug 26.
Reference Type
BACKGROUND
Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, Davis ME. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res. 2006 Mar 1;12(5):1606-14. doi: 10.1158/1078-0432.CCR-05-1566.
Reference Type
BACKGROUND
Numbenjapon T, Wang J, Colcher D, Schluep T, Davis ME, Duringer J, Kretzner L, Yen Y, Forman SJ, Raubitschek A. Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. Clin Cancer Res. 2009 Jul 1;15(13):4365-73. doi: 10.1158/1078-0432.CCR-08-2619. Epub 2009 Jun 23.
Reference Type
BACKGROUND
Pham E, Birrer MJ, Eliasof S, Garmey EG, Lazarus D, Lee CR, Man S, Matulonis UA, Peters CG, Xu P, Krasner C, Kerbel RS. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin Cancer Res. 2015 Feb 15;21(4):808-18. doi: 10.1158/1078-0432.CCR-14-2810. Epub 2014 Dec 18.
Reference Type
BACKGROUND
Gaur S, Chen L, Yen T, Wang Y, Zhou B, Davis M, Yen Y. Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer. Nanomedicine. 2012 Jul;8(5):721-30. doi: 10.1016/j.nano.2011.09.007. Epub 2011 Oct 25.
Reference Type
BACKGROUND
Rapisarda A, Melillo G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol. 2012 Apr 24;9(7):378-90. doi: 10.1038/nrclinonc.2012.64.
Reference Type
BACKGROUND
Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Hewitt SM, Shoemaker RH, Melillo G. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res. 2004 Oct 1;64(19):6845-8. doi: 10.1158/0008-5472.CAN-04-2116.
Reference Type
BACKGROUND
Conley SJ, Baker TL, Burnett JP, Theisen RL, Lazarus D, Peters CG, Clouthier SG, Eliasof S, Wicha MS. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Res Treat. 2015 Apr;150(3):559-67. doi: 10.1007/s10549-015-3349-8. Epub 2015 Apr 2.
Reference Type
BACKGROUND
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N; AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007 Dec 22;370(9605):2103-11. doi: 10.1016/S0140-6736(07)61904-7.
Reference Type
BACKGROUND
Weiss GJ, Chao J, Neidhart JD, Ramanathan RK, Bassett D, Neidhart JA, Choi CHJ, Chow W, Chung V, Forman SJ, Garmey E, Hwang J, Kalinoski DL, Koczywas M, Longmate J, Melton RJ, Morgan R, Oliver J, Peterkin JJ, Ryan JL, Schluep T, Synold TW, Twardowski P, Davis ME, Yen Y. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs. 2013 Aug;31(4):986-1000. doi: 10.1007/s10637-012-9921-8. Epub 2013 Feb 9.
Reference Type
BACKGROUND
Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH; American Society of Clinical Oncology. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. doi: 10.1200/JCO.2011.39.9436. Epub 2012 Apr 2.
Reference Type
BACKGROUND
Viale PH. The American Cancer Society's Facts & Figures: 2020 Edition. J Adv Pract Oncol. 2020 Mar;11(2):135-136. doi: 10.6004/jadpro.2020.11.2.1. Epub 2020 Mar 1. No abstract available.
Reference Type
BACKGROUND
Keefe, SM, Heitjan D, Hennessy M., et al. Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of subjects (pts) with refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol 32, 2014 (suppl 4; abstr 412).
Reference Type
BACKGROUND
Yen et al, Final phase 1/2a results evaluating the cyclodextrin-containing nanoparticle CRLX101 in subjects with advanced solid tumor malignancies, 23rd EORTC-NCI-AACR, Nov 12-16, 2011: abstract A97
Reference Type
BACKGROUND
Guichard S, Arnould S, Hennebelle I, Bugat R, Canal P. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo. Anticancer Drugs. 2001 Oct;12(9):741-51. doi: 10.1097/00001813-200110000-00006.
Reference Type
BACKGROUND
Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res. 1999 May;5(5):1189-96.
Reference Type
BACKGROUND
Bissery MC, Vrignaud P, Lavelle F. In vivo evaluation of the irinotecan-oxaliplatin combination. Proc Am Assoc Cancer Res 1998; 39: 526.
Reference Type
BACKGROUND
Goldwasser F, Bozec L, Zeghari-Squalli N, Misset JL. Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line. Anticancer Drugs. 1999 Feb;10(2):195-201. doi: 10.1097/00001813-199902000-00008.
Reference Type
BACKGROUND
Ychou M, Conroy T, Seitz JF, Gourgou S, Hua A, Mery-Mignard D, Kramar A. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol. 2003 Mar;14(3):481-9. doi: 10.1093/annonc/mdg119.
Reference Type
BACKGROUND
Lee J, Kang WK, Kwon JM, Oh SY, Lee HR, Kim HJ, Park BB, Lim HY, Han MJ, Park JO, Park YS. Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. Ann Oncol. 2007 Jan;18(1):88-92. doi: 10.1093/annonc/mdl317. Epub 2006 Sep 13.
Reference Type
BACKGROUND
Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV; Gynecologic Oncology Group Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005 Jul 20;23(21):4626-33. doi: 10.1200/JCO.2005.10.021. Epub 2005 May 23.
Reference Type
BACKGROUND
Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G; Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007 May 1;25(13):1670-6. doi: 10.1200/JCO.2006.09.0928.
Reference Type
BACKGROUND
Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis Ch, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D, Georgoulias V. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006 Mar 27;94(6):798-805. doi: 10.1038/sj.bjc.6603011.
Reference Type
BACKGROUND
Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014 Oct 23;371(17):1609-18. doi: 10.1056/NEJMoa1403108.
Reference Type
BACKGROUND
Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A, Samalin E, Portales F, Bibeau F, Crapez-Lopez E, Bleuse JP, Ychou M. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist. 2011;16(11):1557-64. doi: 10.1634/theoncologist.2011-0141. Epub 2011 Oct 20.
Reference Type
BACKGROUND
Conroy T, Paillot B, Francois E, Bugat R, Jacob JH, Stein U, Nasca S, Metges JP, Rixe O, Michel P, Magherini E, Hua A, Deplanque G. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol. 2005 Feb 20;23(6):1228-36. doi: 10.1200/JCO.2005.06.050.
Reference Type
BACKGROUND
Ychou M, Desseigne F, Guimbaud R et al. Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O] vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial [abstract]. J Clin Oncol 2007;25(June 20 Suppl):4516.
Reference Type
BACKGROUND
Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.
Reference Type
BACKGROUND
Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015 Oct;16(13):1306-15. doi: 10.1016/S1470-2045(15)00122-9. Epub 2015 Aug 31.
Reference Type
BACKGROUND
Marsh Rde W, Talamonti MS, Katz MH, Herman JM. Pancreatic cancer and FOLFIRINOX: a new era and new questions. Cancer Med. 2015 Jun;4(6):853-63. doi: 10.1002/cam4.433. Epub 2015 Feb 19.
Reference Type
BACKGROUND
Lowery MA, Yu KH, Adel NG et al. Activity of front-line FOLFIRINOX (FFX) in stage III/IV pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer Center (MSKCC) [abstract]. ASCO Meeting Abstracts 2012;30:4057.
Reference Type
BACKGROUND
Clark AJ, Wiley DT, Zuckerman JE, Webster P, Chao J, Lin J, Yen Y, Davis ME. CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing. Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):3850-4. doi: 10.1073/pnas.1603018113. Epub 2016 Mar 21.
Reference Type
BACKGROUND
Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, Rao JJ, Berlin ST, Campos SM, Matulonis UA. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008 Sep;122(3):574-80. doi: 10.1016/j.jaci.2008.02.044. Epub 2008 May 27.
Reference Type
BACKGROUND
Leong S, Eckhardt SG, Chan E, Messersmith WA, Spratlin J, Camidge DR, Diab S, Khosravan R, Lin X, Chow Maneval E, Lockhart AC. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012 Jul;70(1):65-74. doi: 10.1007/s00280-012-1880-4. Epub 2012 May 24.
Reference Type
BACKGROUND
Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO; American Society of Clinical Oncology. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. doi: 10.1200/JCO.2015.62.3488. Epub 2015 Jul 13.
Reference Type
BACKGROUND
Sriram D, Yogeeswari P, Thirumurugan R, Bal TR. Camptothecin and its analogues: a review on their chemotherapeutic potential. Nat Prod Res. 2005 Jun;19(4):393-412. doi: 10.1080/14786410412331299005.
Reference Type
BACKGROUND
Rouch JA, Burton B, Dabb A, Brown V, Seung AH, Kinsman K, Holdhoff M. Comparison of enteral and parenteral methods of urine alkalinization in patients receiving high-dose methotrexate. J Oncol Pharm Pract. 2017 Jan;23(1):3-9. doi: 10.1177/1078155215610914. Epub 2016 Jun 23.
Reference Type
BACKGROUND
Sharma S, Abhyankar V, Burgess RE, Infante J, Trowbridge RC, Tarazi J, Kim S, Tortorici M, Chen Y, Robles RL. A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann Oncol. 2010 Feb;21(2):297-304. doi: 10.1093/annonc/mdp489. Epub 2009 Nov 25.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRLX101-102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03170960
ACTIVE_NOT_RECRUITING
PHASE1
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
NCT02391480
COMPLETED
PHASE1
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03071757
COMPLETED
PHASE1
A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
NCT00422097
COMPLETED
PHASE1
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
NCT01478685
COMPLETED
PHASE1
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
NCT00333502
COMPLETED
PHASE1/PHASE2
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
NCT04272203
TERMINATED
PHASE1
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
NCT04780217
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
NCT03447470
COMPLETED
PHASE1
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
NCT04771520
RECRUITING
PHASE2
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
NCT02543645
TERMINATED
PHASE1
Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors
NCT05571969
SUSPENDED
PHASE1
A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)
NCT03234712
COMPLETED
PHASE1
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
NCT04721015
ACTIVE_NOT_RECRUITING
PHASE1
Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas
NCT03188328
TERMINATED
PHASE1
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
NCT05039801
RECRUITING
PHASE1
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
NCT02365662
TERMINATED
PHASE1
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
NCT03000257
COMPLETED
PHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
NCT06488716
TERMINATED
PHASE1
BMS-247550 in Treating Patients With Advanced Cancers
NCT00006221
COMPLETED
PHASE1
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
NCT02030067
COMPLETED
PHASE1/PHASE2
A Phase I Study of PLX038 in Patients With Advanced Solid Tumors
NCT02646852
COMPLETED
PHASE1
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
NCT00441337
COMPLETED
PHASE1
AVID100 in Advanced Epithelial Carcinomas
NCT03094169
TERMINATED
PHASE1/PHASE2